Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/09/2025 14:55 PDT] Absci Corporation (NASDAQ:ABSI), Up By 100% ($2.24) From $2.24 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/09/2025 07:19 PDT] ABSI Expected to Trade Up After Bullish Patterns Develop
• [04/04/2025 12:04 PDT] Absci Corporation (NASDAQ:ABSI), Down By 100% ($2.4) From $2.4 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/02/2025 07:09 PDT] ABSI Expected to Trade Down After Bearish Patterns Develop